Finance

Lists
Why is Q910 up 2,85%?
Dive Deeper
Q910:FRA
Annexin Pharmaceuticals AB (publ)
0,79 €
+2,85%
(+0,022) 1D
12 հոկ, 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for Q910...
Open
0,79 €
High
0,79 €
Low
0,79 €
Mkt. cap
74,98 մլն
Avg. vol.
70,00
Volume
0,00
52-wk high
2,58 €
52-wk low
0,76 €
No. of employees
4
Open
0,79 €
High
0,79 €
Low
0,79 €
Mkt. cap
74,98 մլն
Avg. vol.
70,00
Volume
0,00
52-wk high
2,58 €
52-wk low
0,76 €
No. of employees
4
News stories
From web sources and news partners
About Annexin Pharmaceuticals AB (publ)
CEO-
Employees4
Founded2014
Headquarters-
Sector-
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7,05 մլն
8,00 մլն
7,92 մլն
8,48 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,35 մլն
2,26 մլն
2,90 մլն
2,96 մլն
Operating expense
9,40 մլն
10,26 մլն
10,82 մլն
11,14 մլն
Total operating expenses
9,40 մլն
10,26 մլն
10,82 մլն
11,14 մլն
Operating income
-9,40 մլն
-10,26 մլն
-10,82 մլն
-11,14 մլն
Other non operating income
-
-
-
1,00 հզր
EBT including unusual items
-9,90 մլն
-10,52 մլն
-10,52 մլն
-11,56 մլն
EBT excluding unusual items
-9,90 մլն
-10,52 մլն
-10,52 մլն
-11,56 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-288,00 հզր
Net income
-9,90 մլն
-10,52 մլն
-10,52 մլն
-11,56 մլն
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
154,00 հզր
231,00 հզր
34,00 հզր
-
Interest expense
-
-
-
-
Net interest expenses
154,00 հզր
231,00 հզր
34,00 հզր
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-9,35 մլն
-10,21 մլն
-10,77 մլն
-11,10 մլն
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps